Jpmorgan Chase & CO Bio Atla, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BCAB
# of Institutions
64Shares Held
17.3MCall Options Held
500Put Options Held
33.5K-
Israel Englander Millennium Management LLC | New York, Ny2.66MShares$3.7 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.52MShares$3.5 Million0.38% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.89MShares$2.62 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.86MShares$2.58 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA874KShares$1.21 Million0.13% of portfolio
About BioAtla, Inc.
- Ticker BCAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,304,100
- Market Cap $50.5M
- Description
- BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...